Optimal combination of immune cells for predicting outcomes in ESCC patients following neoadjuvant immunochemotherapy: Results from a prospective phase II trial.

Genes Dis · 2026 · PMC13355625 · PMID 42437048

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

There was a clear trend indicating that high expression of CD74 was associated with poor disease-free survival in ESCC patients receiving NeoICT, although it was not statistically significant at that point ( p = 0.081; Fig.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.